DE602004006633D1 - Verwendung von dapson als neuroprotektor bei zerebralinfarkt - Google Patents

Verwendung von dapson als neuroprotektor bei zerebralinfarkt

Info

Publication number
DE602004006633D1
DE602004006633D1 DE602004006633T DE602004006633T DE602004006633D1 DE 602004006633 D1 DE602004006633 D1 DE 602004006633D1 DE 602004006633 T DE602004006633 T DE 602004006633T DE 602004006633 T DE602004006633 T DE 602004006633T DE 602004006633 D1 DE602004006633 D1 DE 602004006633D1
Authority
DE
Germany
Prior art keywords
dapsone
stroke
neuroprotektor
cerebralinfarts
brain stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004006633T
Other languages
English (en)
Other versions
DE602004006633T2 (de
Inventor
Castaneda Luis Camilo Rios
Martinez Marina Cal Altagracia
Kawachi Juan Puente De P Nader
Jinich J Kravzov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INST NACIONAL DE NEUROLOGIA Y
Universidad Autonoma Metropolitana (UAM)
Original Assignee
INST NACIONAL DE NEUROLOGIA Y
Universidad Autonoma Metropolitana (UAM)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INST NACIONAL DE NEUROLOGIA Y, Universidad Autonoma Metropolitana (UAM) filed Critical INST NACIONAL DE NEUROLOGIA Y
Publication of DE602004006633D1 publication Critical patent/DE602004006633D1/de
Application granted granted Critical
Publication of DE602004006633T2 publication Critical patent/DE602004006633T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Mobile Radio Communication Systems (AREA)
DE602004006633T 2003-07-22 2004-03-16 Verwendung von dapson als neuroprotektor bei zerebralinfarkt Expired - Lifetime DE602004006633T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MXPA03006549 2003-07-22
MXPA03006549A MXPA03006549A (es) 2003-07-22 2003-07-22 Uso de la dapsona como neuroprotector en el infarto cerebral.
PCT/MX2004/000018 WO2005007239A1 (es) 2003-07-22 2004-03-16 Uso de la dapsona como neuroprotector en el infarto cerebral

Publications (2)

Publication Number Publication Date
DE602004006633D1 true DE602004006633D1 (de) 2007-07-05
DE602004006633T2 DE602004006633T2 (de) 2008-01-31

Family

ID=34075071

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004006633T Expired - Lifetime DE602004006633T2 (de) 2003-07-22 2004-03-16 Verwendung von dapson als neuroprotektor bei zerebralinfarkt

Country Status (15)

Country Link
US (1) US8268893B2 (de)
EP (1) EP1655055B1 (de)
JP (1) JP5452844B2 (de)
CN (1) CN100500246C (de)
AT (1) ATE362783T1 (de)
BR (1) BRPI0412212A (de)
CA (1) CA2533181C (de)
DE (1) DE602004006633T2 (de)
EA (1) EA012174B1 (de)
EC (1) ECSP066316A (de)
ES (1) ES2287713T3 (de)
HK (1) HK1098086A1 (de)
MX (1) MXPA03006549A (de)
PT (1) PT1655055E (de)
WO (1) WO2005007239A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009004635A (es) * 2009-04-29 2010-10-29 Univ Autonoma Metropolitana Formas farmaceúticas solubles de la n,n´-diamino-difenilsulfona para su uso óptimo en el tratamiento de diversas enfermedades.
KR101875705B1 (ko) * 2011-12-07 2018-07-06 삼성전자주식회사 디아미노디페닐술폰을 포함하는 근육 소모 관련 질환의 예방 또는 치료용 약학적 조성물
CN104177610A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN104177611A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN104069091A (zh) * 2014-07-09 2014-10-01 崔德华 氨苯砜在保护血脑屏障完整性中的应用
KR20160047318A (ko) * 2014-10-22 2016-05-02 삼성전자주식회사 다프손을 포함하는, 개체의 부위에서 혈관신생을 자극시키기 위한 조성물 및 그의 용도
KR20200107899A (ko) * 2019-11-16 2020-09-16 이종훈 알츠하이머병 혹은 뇌졸중의 뉴로인플라마섬의 치료제로서 디디에스 혹은 그 유도체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532219A (en) * 1991-04-23 1996-07-02 The University Of British Columbia Dapsone and promin for the treatment of dementia
JP2002520419A (ja) * 1998-07-15 2002-07-09 ヨマー、ハッサン リン有機化合物およびその使用
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
HK1098086A1 (en) 2007-07-13
CN100500246C (zh) 2009-06-17
EP1655055B1 (de) 2007-05-23
US20100063159A1 (en) 2010-03-11
CA2533181A1 (en) 2005-01-27
EA200600272A1 (ru) 2006-10-27
DE602004006633T2 (de) 2008-01-31
US8268893B2 (en) 2012-09-18
WO2005007239B1 (es) 2005-05-06
EP1655055A1 (de) 2006-05-10
EA012174B1 (ru) 2009-08-28
ECSP066316A (es) 2006-10-25
ES2287713T3 (es) 2007-12-16
PT1655055E (pt) 2007-08-31
JP5452844B2 (ja) 2014-03-26
CN1852749A (zh) 2006-10-25
BRPI0412212A (pt) 2006-08-22
ATE362783T1 (de) 2007-06-15
JP2006528175A (ja) 2006-12-14
CA2533181C (en) 2012-08-07
MXPA03006549A (es) 2004-03-18
WO2005007239A1 (es) 2005-01-27

Similar Documents

Publication Publication Date Title
BR0114054A (pt) Método para tratar alergias usando pirazóis substituìdos
ECSP066316A (es) Uso de la dapsona como neuroprotector en el infarto cerebral
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
HK1069767A1 (en) Methods for inhibiting ocular processes
DE60237725D1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
EA200300027A1 (ru) Способ лечения сердечно-сосудистых заболеваний
HRP20020593B1 (en) Brain, spinal and nerve injury treatment
ATE518952T1 (de) Bispezifischer antikörper als ersatz für factor viii
DE602006008643D1 (de) Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie
WO2007103380A3 (en) Monitoring and quantification of smoking behaviors
BR0316438A (pt) Uso de eritropoietina em doenças cardìacas
DE602006008641D1 (de) Herstellung und anwendung von tetrahydropyrrolo ä3, 2-cüpyridin-4-onderivaten zur behandlung von obesitas und psychiatrischen und neurologischen erkrankungen
EA200400518A1 (ru) Способы лечения глазных неоваскулярных заболеваний
MXPA04001088A (es) Derivados de pirazol como inhibidores de cinasa y uso de los mismos.
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE60323994D1 (de) Verfahren zur herstellung von 2-chlor-1,1,1,2,3,3,3-heptafluorpropan, hexafluorpropen und 1,1,1,2,3,3,3-heptafluorpropan
DE60304695D1 (de) 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN
ATE399557T1 (de) Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
ATE424825T1 (de) Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
ATE556707T1 (de) Phosphodiesesterase 4 inhibitoren zur behandlung eines kognitiven defizits
ATE552251T1 (de) Thiophen- und furanverbindungen
DE602005017762D1 (de) Methode zur behandlung trockener augen und uveitis
DE602004026597D1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
MXPA05002418A (es) Derivados de 1,4-pirazina sustituidos.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition